WEX Analyst Highlights Cost Savings, Cross-Sell Revenue Potential Post Q3 Beat
Credit Suisse analyst Nik Cremo reiterated Neutral on WEX Inc (NYSE: WEX) with a $195 price target.
WEX's Q3 2022 revenue exceeded consensus estimates by 5%, with help from higher fuel prices, deposit revenue, and higher-than-expected late fees. Meanwhile, Q3 adjusted EPS beat consensus by a smaller margin of +2% due to higher-than-expected credit losses attributable to smaller OTR fleets and fraud losses that remained elevated at ~11bps.
Cremo highlighted WEX's plans to deliver $100 million in run-rate operating expense savings by the end of 2024 (but plans to reinvest ~50%) and mentioned the potential to exit 2023 at a ~$50 million -$65 million run-rate.
He emphasized the disclosure of ~$28 million in Q3 run-rate Corporate Payments cross-sell revenue to WEX's larger OTR (Fleet) customers and that the company is now working through a qualified sales lead list.
He noted that WEX launched Flume on schedule in Q3, its SMB direct solution to help businesses pay and get paid, and has begun cross-selling the product to its >450,000 SMB fuel customers.
Barclays analyst Ramsey El-Assal maintained WEX with an Overweight and raised the price target from $211 to $213.
Price Action: WEX shares traded higher by 1.14% at $164.67 on the last check Monday.
Latest Ratings for WEX
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | Mizuho | Maintains | Buy | |
Feb 2022 | Credit Suisse | Maintains | Neutral | |
Jan 2022 | Mizuho | Maintains | Buy |
View More Analyst Ratings for WEX
View the Latest Analyst Ratings
See more from Benzinga
Nvidia Is The Best Artificial Intelligence and Machine Learning Play, Analyst Says
KeyBanc Sees This Woman-Centric Dating Platform Sustaining Growth
Edward Snowden Says 'We Are All Going To Be Billionaires' But...
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.